Rituximab: Applications in dermatology

International Journal of Dermatology

Volumn 45, Issue 10, 2006, Pages 1143-1155

  Fatourechi, Mitra M ^a,b   el Azhary, Rokea A ^a,b   Gibson, Lawrence E ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DNA TOPOISOMERASE; DOXORUBICIN; GOLD; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RETINAL; RITUXIMAB; SUCRALFATE; VINCRISTINE;

ALOPECIA; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CHILL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DERMATOMYOSITIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEVER; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INTERSTITIAL PNEUMONIA; KAPOSI SARCOMA; LEUKOPENIA; MANTLE CELL LYMPHOMA; MELANOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PEMPHIGUS; PEMPHIGUS VULGARIS; PNEUMOCYSTIS PNEUMONIA; RASH; RHEUMATOID ARTHRITIS; SCLERODERMA; SEPSIS; SKIN CANCER; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN LYMPHOMA; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; VIRUS REACTIVATION; VITILIGO;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 33749836966     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.03007.x     Document Type: Article

References (94)

1. Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-1685.
2. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48: 1484-1492.
3. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
4. O'Keefe TL, Williams GT, Davies SL, et al. Mice carrying a CD20 gene disruption. Immunogenetics 1998; 48: 125-132.
5. Terstappen LW, Johnsen S, Segers-Nolten IM, et al. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990; 76: 1739-1747.
6. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
7. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-888.
8. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
9. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 34: 445-450.
10. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17: 791-795.
11. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608.
12. Swords R, Power D, Fay M, et al. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004; 77: 103-104.
13. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348: 2690-2691.
14. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: 2691-2694.
15. Hofer S, Viollier R, Ludwig C. Delayed-onset and long-lasting severe neutropenia due to rituximab. Swiss Med Wkly 2004; 134: 79-80.
16. Clifford KS, Demierre MF. Progression of classic Kaposi's sarcoma with rituximab. J Am Acad Dermatol 2005; 53: 155-157.
17. Lowndes S, Darby A, Mead G, et al. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-1950.
18. Heinzerling L, Dummer R, Kempf W, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000; 136: 374-378.
19. Paul T, Radny P, Krober SM, et al. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001; 144: 1239-1243.
20. Roguedas AM, Watier H, Paintaud G, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: Local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 2005; 152: 541-544.
21. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
22. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
23. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
24. Kojouri K, George JN. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol 2005; 81: 119-125.
25. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion in rheumatoid arthritis: Targeting of CD20. Curr Dir Autoimmun 2005; 8: 175-192.
26. Keogh KA, Wylam ME, Stone JH, et al. Induction of remission by B lymphocyte depletion in 11 patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-268.
27. Looney RJ, Anolik JH, Campbell D, et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-esclation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
28. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
29. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
30. Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-1844.
31. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.
32. Imai Y, Isoda K, Ito E, et al. Primary cutaneous follicle center cell lymphoma of the scalp successfully treated with anti CD20 monoclonal antibody and CHOP combination therapy with no subsequent permanent loss of hair. J Dermatol 2003; 30: 683-688.
33. Lacouture ME, Baron JM, Jani AB, et al. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Clin Exp Dermatol 2005; 30: 46-48.
34. Goto H, Nishio M, Endo T, et al. Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma. Eur J Haematol 2005; 74: 526-528.
35. Gellrich S, Muche JM, Wilks A, et al. Systemic 8-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas: An applicational observation. Br J Dermatol 2005; 153: 167-173.
36. Fink-Puches R, Wolf IH, Zalaudek I, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005; 52: 847-853.
37. Lami MC, Vabres P, Dreyfus B, et al. Primary cutaneous B-cell lymphoma mimicking pyoderma gangrenosum: First-line treatment with rituximab. Br J Dermatol 2004; 151: 250-252.
38. Kennedy GA, Blum R, McCormack C, et al. Treatment of primary cutaneous follicular centre lymphoma with rituximab: A report of two cases. Australas J Dermatol 2004; 45: 34-37.
39. Han K, Haley JC, Carlson K, et al. Regression of cutaneous intravascular lymphoma with rituximab. Cutis 2003; 72: 137-140.
40. Fierro MT, Savoia P, Quaglino P, et al. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: A report of 7 cases. J Am Acad Dermatol 2003; 49: 281-287.
41. Brogan BL, Zic JA, Kinney MC, et al. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a north American series. J Am Acad Dermatol 2003; 49: 223-228.
42. Massengale WT, McBurney E, Gurtler J. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. J Am Acad Dermatol 2002; 46: 441-443.
43. Garbea A, Dippel E, Hildenbrand R, et al. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol 2002; 146: 144-147.
44. Bonnekoh B, Schulz M, Franke I, Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monitherapy with the CD20-antibody rituximab. J Cancer Res Clin Oncol 2002; 128: 161-166.
45. Soda R, Costanzo A, Cantonetti M, et al. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 2001; 81: 207-208.
46. Aboulafia DM. Primary cutaneous large B-cell lymphoma of the legs: A distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am J Clin Oncol 2001; 24: 237-240.
47. Sabroe RA, Child FJ, Woolford AJ, et al. Rituximab in cutaneous B-cell lymphoma: A report of two cases. Br J Dermatol 2000; 143: 157-161.
48. Vedrine L, Fromatin I, Vincet-Salomon A, et al. Skin lymphomatous lesions treated by rituximab: A necrotic life-threatening evolution. Leuk Lymphoma 2004; 45: 1717-1718.
49. Clarke LE, Bayerl MG, Ehmann WC, et al. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. J Cutan Pathol 2003; 30: 459-462.
50. Zinzani PL, Stefoni V, Alinari L, et al. Rituximab in heavily pretreated cutaneous B-cell lymphoma. Leuk Lymphoma 2003; 44: 1637-1638.
51. Ferrer A, Lopez-Guillermo A, Montoto S, et al. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. Ann Hematol 2001; 80: 479-481.
52. Cohen Y, Libster D, Da'as N, et al. Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab. Hematol J 2003; 4: 151-153.
53. Schmook T, Stockfleth E, Lischner S, et al. Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP). Clin Exp Dermatol 2003; 28: 31-33.
54. Sebire NJ, Haselden S, Malone M, et al. Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol 2003; 56: 555-557.
55. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus: An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-1735.
56. Anhalt GJ. Paraneoplastic pemphigus. J Invest Dermatol Symp Proc 2004; 9: 29-33.
57. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993; 129: 883-886.
58. Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20 (+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001; 137: 269-272.
59. Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001; 66: 142-144.
60. Ahmed AR, Avram MM, Duncan LM. Case records of the Massachusetts General Hospital: Weekly clinicopathological exercisesA case 23-2003: a 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med 2003; 349: 382-391.
61. Van Rossum MM, Verhaegen NT, Jonkman MF, et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: Case report with review of novel treatment modalities. Leuk Lymphoma 2004; 45: 2327-2332.
62. Perniciaro C, Kuechle MK, Colon-Otero G, et al. Paraneoplastic pemphigus: A case of prolonged survival. Mayo Clin Proc 1994; 69: 851-855.
63. Gergely L, Varoczy L, Vadasz G, et al. Successful treatment of B-cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporine A. Acta Haematol 2003; 109: 202-205.
64. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47: 785-788.
65. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases: Successful result in refractory pemphigus vulgaris: Report of a case. Haematologica 2003; 88: ELT24.
66. Cooper HL, Healy E, Theaker JM, et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol 2003; 28: 366-368.
67. Espana A, Fernandez-Galar M, Lloret P, et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004; 50: 974-976.
68. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51: 817-819.
69. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91-96.
70. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148: 602-603.
71. Goebeler M, Herzog S, Brocker EB, et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149: 899-901.
72. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133: 275-279.
73. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505-511.
74. Szabolcs P, Reese M, Yancey KB, et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30: 327-329.
75. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004; 104: 2603-2606.
76. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol 1998; 134: 602-612.
77. Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005; 52: 601-607.
78. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 138: 99-105.
79. Cepeda EJ, Reveille JD. Auto-antibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance. Curr Opin Rheumatol 2004; 16: 723-732.
80. Hayakawa I, Hasegawa M, Takehara K, et al. Anti-DNA topoisomerase IIα autoantibodies in localized scleroderma. Arthritis Rheum 2004; 50: 227-232.
81. Nagai M, Hasegawa M, Takehara K, et al. Novel auto-antibody to Cu/Zn superoxide dismutase in patients with localized scleroderma. J Invest Dermatol 2004; 122: 594-601.
82. Whitfield ML, Finaly DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-12324.
83. Roumm AD, Whiteside TL, Medsger TA Jr, et al. Lymphocytes in the skin of patients with progressive systemic sclerosis: Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984; 27: 645-653.
84. Saigal K, Valencia IC, Cohen J, et al. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: Rapid response to rituximab. J Am Acad Dermatol 2003; 49: S283-S285.
85. Muwakkit S, Locatelli F, Abboud M, et al. Report of a child with vitiligo and Evans syndrome. J Pediatr Hematol Oncol 2003; 25: 344-345.
86. Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293: 730-735.
87. Betterle C, Caretto A, De Zio A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only auto-antibodies) in patients with vitiligo. Dermatologica 1985; 171: 419-423.
88. Naughton GK, Eisinger M, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81: 540-542.
89. Norris DA, Kissinger RM, Naughton GM, et al. Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90: 783-789.
90. Aklilu M, Stadler WM, Markiewicz M, et al. Depletion of normal B-cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 2004; 15: 1109-1114.
91. Lugovic L, Lipozenocic J, Jakic-Razumovic J. Atopic dermatitis: immunophenotyping of inflammatory cells in skin lesions. Int J Dermatol 2001; 40: 489-494.
92. Hainsworth JD. Safety of rituximab in the treatment of B-cell malignancies: Implications for rheumatoid arthritis. Arthritis Res Ther 2003; 5: S12-S16.
93. Slifka MK, Ahmed R. Long-lived plasma cells: A mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10: 252-258.
94. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61: 922-924.